Condition: Solid Tumor, Adult · Solid Tumor · Melanoma · Sponsor: Rise Therapeutics LLC
The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.
This description comes directly from the study's public registry record.
Janet Stephens, PhD · 650-417-8556 · jstephens@risetherapeutics.com
Christian Freguia, PhD · 215-923-1818 · cfreguia@risetherapeutics.com
Always discuss trial participation with your own doctor first.
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06398418